HRP20210301T1 - Djelotvorna selektivnost rekombinantnih proteina - Google Patents
Djelotvorna selektivnost rekombinantnih proteina Download PDFInfo
- Publication number
- HRP20210301T1 HRP20210301T1 HRP20210301TT HRP20210301T HRP20210301T1 HR P20210301 T1 HRP20210301 T1 HR P20210301T1 HR P20210301T T HRP20210301T T HR P20210301TT HR P20210301 T HRP20210301 T HR P20210301T HR P20210301 T1 HRP20210301 T1 HR P20210301T1
- Authority
- HR
- Croatia
- Prior art keywords
- goi
- seq
- cell
- fragment
- antigen
- Prior art date
Links
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 102000003886 Glycoproteins Human genes 0.000 claims 8
- 108090000288 Glycoproteins Proteins 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 6
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (15)
1. Izolirana stanica, naznačena time što sadrži:
(a) sisavački gen za otpornost na tunikamicin (Tn) koji kodira protein koji je najmanje 93% istovjetan aminokiselinskom slijedu u SEQ ID NO: 3, gdje je gen za otpornost na Tn egzogeno dodan u stanicu;
(b) prvi gen od interesa (GOI), gdje je prvi GOI egzogeno dodani GOI; i
(c) najmanje jedan regulacijski element
gdje je gen za otpornost na Tn operabilno vezan na prvi GOI i najmanje jedan regulacijski element, gdje stanica je sisavačka stanica, i, naznačen time što prvi GOI kodira laki lanac protutijela ili njegov fragment koji se veže na antigen, teški lanac protutijela ili njegov fragment koji se veže na antigen, ili Fc-fuzijski protein ili njegov fragment.
2. Vektor koji sadrži nukleinsku kiselinu, naznačen time što nukleinska kiselina sadrži sisavački gen za otpornost na tunikamicin (Tn) koji kodira protein koji je najmanje 93% istovjetan aminokiselinskom slijedu u SEQ ID NO: 3, prvi gen od interesa (GOI) operabilno vezan na Tn-otpornost gen, te najmanje jedan regulacijski element, te gdje prvi GOI kodira laki lanac protutijela ili njegov fragment koji se veže na antigen, teški lanac protutijela ili njegov fragment koji se veže na antigen, ili Fc-fuzijski protein ili njegov fragment.
3. Izolirana stanica u skladu s patentnim zahtjevom 1, ili vektor u skladu s patentnim zahtjevom 2, naznačeni time što gen za otpornost na Tn sadrži nukleinskokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO 2, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, te SEQ ID NO: 17.
4. Izolirana stanica u skladu s patentnim zahtjevom 1, ili vektor u skladu s patentnim zahtjevom 2, naznačeni time što se najmanje jedan regulacijski element bira iz skupine koju čine promotor, mjesto vezanja na ribosom, te pojačivač.
5. Izolirana stanica u skladu s patentnim zahtjevom 1, ili vektor u skladu s patentnim zahtjevom 2, naznačeni time što je prvi GOI operabilno vezan na promotor.
6. Izolirana stanica u skladu s patentnim zahtjevom 1, ili vektor u skladu s patentnim zahtjevom 2, naznačeni time što dodatno sadrže drugi egzogeno dodani gen od interesa (GOI), gdje drugi GOI može kodirati glikoprotein, gdje se glikoprotein može birati između lakog lanca protutijela ili njegovog fragmenta koji se veže na antigen, teškog lanca protutijela ili njegovog fragmenta koji se veže na antigen, Fc-fuzijskog proteina ili njegovog fragmenta, liganda, te receptora ili njegovog fragmenta koji se veže na ligand.
7. Postupak, naznačen time što se sastoji u:
(a) unosu vektora koji sadrži nukleinsku kiselinu u populaciju sisavačkih stanica domaćina transficiranjem, gdje nukleinska kiselina sadrži sisavački gen za otpornost na tunikamicin (Tn) koji kodira protein koji je najmanje 93% istovjetan aminokiselinskom slijedu u SEQ ID NO: 3, prvi gen od interesa (GOI) operabilno vezan na Tn-otpornost gen, te najmanje jedan regulacijski element;
(b) uzgoju stanične populacije iz koraka (a) u prisutnosti Tn, čime se dobije transficiranu stanicu koja sadrži nukleinska kiselina iz vektora.
8. Postupak proizvodnje rekombinantnog proteina od interesa (POI), naznačen time što se postupak sastoji u:
(a) osiguravanju sisavačke stanice domaćina koja sadrži:
(i) sisavački gen za otpornost na tunikamicin (Tn) koji kodira protein koji je najmanje 93% istovjetan aminokiselinskom slijedu u SEQ ID NO: 3, gdje je gen za otpornost na Tn egzogeno dodan u stanicu;
(ii) prvi gen od interesa (GOI), gdje je prvi GOI egzogeno dodani GOI; i
(iii) najmanje jedan regulacijski element, gdje je gen za otpornost na Tn operabilno vezan na prvi GOI i najmanje jedan regulacijski element; i
(b) uzgoju stanice u prisutnosti Tn radi eksprimiranja POI iz GOI.
9. Postupak u skladu s patentnim zahtjevom 7 ili 8, naznačen time što:
(i) gen za otpornost na Tn sadrži nukleinskokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, te SEQ ID NO: 17;
(ii) najmanje jedan regulacijski element se bira iz skupine koju čine promotor, mjesto vezanja na ribosom, te pojačivač;
(iii) prvi GOI je operabilno vezan na promotor; i/ili
(iv) prvi GOI kodira glikoprotein, gdje se glikoprotein može birati između lakog lanca protutijela ili njegovog fragmenta koji se veže na antigen, teškog lanca protutijela ili njegovog fragmenta koji se veže na antigen, Fc-fuzijskog proteina ili njegovog fragmenta, liganda, te receptora ili njegovog fragmenta koji se veže na ligand.
10. Postupak u skladu s patentnim zahtjevom 7, naznačen time što vektor dodatno sadrži drugi egzogeno dodani gen od interesa (GOI), gdje drugi GOI može kodirati glikoprotein, gdje se glikoprotein može birati između lakog lanca protutijela ili njegovog fragmenta koji se veže na antigen, teškog lanca protutijela ili njegovog fragmenta koji se veže na antigen, Fc-fuzijskog proteina ili njegovog fragmenta, liganda, te receptora ili njegovog fragmenta koji se veže na ligand.
11. Postupak u skladu s patentnim zahtjevom 8, naznačen time što sisavačka stanica dodatno sadrži drugi egzogeno dodani gen od interesa (GOI), gdje drugi GOI može kodirati glikoprotein, gdje se glikoprotein može birati između lakog lanca protutijela ili njegovog fragmenta koji se veže na antigen, teškog lanca protutijela ili njegovog fragmenta koji se veže na antigen, Fc-fuzijskog proteina ili njegovog fragmenta, liganda, te receptora ili njegovog fragmenta koji se veže na ligand.
12. Postupak u skladu s bilo kojim od patentnih zahtjeva 7-11, naznačen time što je Tn u koncentraciji od najmanje 1 µg/ml po mogućnosti gdje je Tn u koncentraciji od 1 µg/ml 2,5 µg/ml ili 5 µg/ml.
13. Postupak u skladu s patentnim zahtjevom 7, naznačen time što se transficiranu stanicu dobije uzgojem stanične populacije iz koraka (b) u prisutnosti stupnjevito sve većih koncentracija Tn, ili postupak u skladu s patentnim zahtjevom 8, gdje se uzgoj sastoji u uzgoju u prisutnosti stupnjevito sve većih koncentracija Tn, gdje se uzgoj može sastojati u uzgoju uz prvu koncentraciju Tn od 1 µg/ml, uz daljnji uzgoj uz drugu koncentraciju Tn od 2,5 µg/ml ili 5 µg/ml.
14. Postupak u skladu s bilo kojim od patentnih zahtjeva 7-11 i 13, naznačen time što dodatno uključuje izdvajanje POI kojeg eksprimira GOI.
15. Izolirana stanica u skladu s bilo kojim od patentnih zahtjeva 1 i 3-6, ili postupak u skladu s bilo kojim od patentnih zahtjeva 7-14, naznačeni time što se stanicu: (a) bira iz skupine koju čine CHO-K1, COS-7, HEK293, tumorska stanica, limfocit, stanica mrežnice, te matična stanica; ili (b) CHO-K1 stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039416P | 2014-08-19 | 2014-08-19 | |
| EP15833421.9A EP3183359B1 (en) | 2014-08-19 | 2015-08-19 | Efficient selectivity of recombinant proteins |
| PCT/US2015/045793 WO2016028838A1 (en) | 2014-08-19 | 2015-08-19 | Efficient selectivity of recombinant proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210301T1 true HRP20210301T1 (hr) | 2021-04-02 |
Family
ID=55347784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210301TT HRP20210301T1 (hr) | 2014-08-19 | 2021-02-23 | Djelotvorna selektivnost rekombinantnih proteina |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9732357B2 (hr) |
| EP (2) | EP3901274A1 (hr) |
| JP (3) | JP7115851B2 (hr) |
| KR (2) | KR102406976B1 (hr) |
| CN (2) | CN107075549B (hr) |
| AR (1) | AR102333A1 (hr) |
| AU (3) | AU2015305565B9 (hr) |
| BR (1) | BR112017003074A2 (hr) |
| CA (1) | CA2957036A1 (hr) |
| CY (1) | CY1124079T1 (hr) |
| DK (1) | DK3183359T3 (hr) |
| EA (1) | EA035340B1 (hr) |
| ES (1) | ES2849728T3 (hr) |
| HR (1) | HRP20210301T1 (hr) |
| HU (1) | HUE054069T2 (hr) |
| IL (3) | IL287020B (hr) |
| LT (1) | LT3183359T (hr) |
| MA (1) | MA40371B1 (hr) |
| MX (2) | MX2017002203A (hr) |
| MY (1) | MY191745A (hr) |
| PL (1) | PL3183359T3 (hr) |
| PT (1) | PT3183359T (hr) |
| RS (1) | RS61371B1 (hr) |
| SG (2) | SG10201707859RA (hr) |
| SI (1) | SI3183359T1 (hr) |
| TW (3) | TWI777374B (hr) |
| WO (1) | WO2016028838A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102333A1 (es) | 2014-08-19 | 2017-02-22 | Regeneron Pharma | Selectividad eficiente de proteínas recombinadas |
| EP3749754A4 (en) * | 2018-02-08 | 2021-10-20 | Applied Stemcell, Inc. | PROCEDURE FOR SCREENING VARIANTS OF A TARGET |
| WO2021079909A1 (ja) | 2019-10-23 | 2021-04-29 | キヤノン株式会社 | セラミックス物品の製造方法およびセラミックス物品 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| US6919183B2 (en) | 2001-01-16 | 2005-07-19 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| ATE496134T1 (de) | 2002-03-29 | 2011-02-15 | Xoma Technology Ltd | Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| JP2005027599A (ja) * | 2003-07-09 | 2005-02-03 | Nara Institute Of Science & Technology | 植物由来遺伝子を用いた遺伝子導入植物の選抜法 |
| EP1586585A1 (de) * | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| CA2671365C (en) | 2006-12-07 | 2020-07-21 | Dow Agrosciences Llc | Use of dsm-2 gene as a selectable marker for selecting herbicidal resistant plants |
| PL2150617T3 (pl) | 2007-06-04 | 2015-04-30 | Regeneron Pharma | Wzmocniona ekspresja i regiony stabilności |
| KR100927803B1 (ko) * | 2007-11-23 | 2009-11-23 | 한국생명공학연구원 | 식물 형질전환체를 선별하기 위한 마커로서 ｇｐｔ 유전자 |
| ME03057B (me) * | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Molekuli humanizovanih antitela specifični za il-31 |
| WO2009131681A2 (en) * | 2008-04-22 | 2009-10-29 | Rutgers, The State University | Hcv e2 construct compositions and methods |
| WO2010077297A1 (en) * | 2008-12-09 | 2010-07-08 | Halozyme, Inc. | Extended soluble ph20 polypeptides and uses thereof |
| EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
| AR102333A1 (es) | 2014-08-19 | 2017-02-22 | Regeneron Pharma | Selectividad eficiente de proteínas recombinadas |
-
2015
- 2015-08-14 AR ARP150102631A patent/AR102333A1/es unknown
- 2015-08-17 TW TW110101888A patent/TWI777374B/zh active
- 2015-08-17 TW TW104126657A patent/TWI719945B/zh active
- 2015-08-17 TW TW111129504A patent/TWI832364B/zh active
- 2015-08-19 SI SI201531487T patent/SI3183359T1/sl unknown
- 2015-08-19 BR BR112017003074-8A patent/BR112017003074A2/pt active Search and Examination
- 2015-08-19 EA EA201790241A patent/EA035340B1/ru unknown
- 2015-08-19 MY MYPI2017700248A patent/MY191745A/en unknown
- 2015-08-19 WO PCT/US2015/045793 patent/WO2016028838A1/en active Application Filing
- 2015-08-19 ES ES15833421T patent/ES2849728T3/es active Active
- 2015-08-19 HU HUE15833421A patent/HUE054069T2/hu unknown
- 2015-08-19 EP EP20211902.0A patent/EP3901274A1/en active Pending
- 2015-08-19 IL IL287020A patent/IL287020B/en unknown
- 2015-08-19 KR KR1020177006620A patent/KR102406976B1/ko active IP Right Grant
- 2015-08-19 CA CA2957036A patent/CA2957036A1/en active Pending
- 2015-08-19 AU AU2015305565A patent/AU2015305565B9/en active Active
- 2015-08-19 JP JP2017509733A patent/JP7115851B2/ja active Active
- 2015-08-19 PT PT158334219T patent/PT3183359T/pt unknown
- 2015-08-19 KR KR1020227018877A patent/KR102556383B1/ko active IP Right Grant
- 2015-08-19 MA MA40371A patent/MA40371B1/fr unknown
- 2015-08-19 CN CN201580044100.7A patent/CN107075549B/zh active Active
- 2015-08-19 US US14/829,834 patent/US9732357B2/en active Active
- 2015-08-19 PL PL15833421T patent/PL3183359T3/pl unknown
- 2015-08-19 CN CN202110402963.4A patent/CN113293139A/zh active Pending
- 2015-08-19 EP EP15833421.9A patent/EP3183359B1/en active Active
- 2015-08-19 SG SG10201707859RA patent/SG10201707859RA/en unknown
- 2015-08-19 LT LTEP15833421.9T patent/LT3183359T/lt unknown
- 2015-08-19 DK DK15833421.9T patent/DK3183359T3/da active
- 2015-08-19 SG SG11201701121UA patent/SG11201701121UA/en unknown
- 2015-08-19 RS RS20210103A patent/RS61371B1/sr unknown
- 2015-08-19 MX MX2017002203A patent/MX2017002203A/es unknown
-
2017
- 2017-02-09 IL IL250531A patent/IL250531B/en unknown
- 2017-02-17 MX MX2021009154A patent/MX2021009154A/es unknown
- 2017-07-31 US US15/664,444 patent/US10457959B2/en active Active
-
2019
- 2019-09-10 US US16/566,253 patent/US11085053B2/en active Active
-
2020
- 2020-07-17 AU AU2020205336A patent/AU2020205336B2/en active Active
- 2020-08-05 JP JP2020132874A patent/JP7260510B2/ja active Active
-
2021
- 2021-02-08 CY CY20211100104T patent/CY1124079T1/el unknown
- 2021-02-23 HR HRP20210301TT patent/HRP20210301T1/hr unknown
- 2021-07-02 US US17/366,239 patent/US20210340564A1/en active Pending
-
2022
- 2022-08-04 IL IL295361A patent/IL295361B2/en unknown
-
2023
- 2023-02-10 AU AU2023200752A patent/AU2023200752B2/en active Active
- 2023-04-06 JP JP2023061971A patent/JP2023076667A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210301T1 (hr) | Djelotvorna selektivnost rekombinantnih proteina | |
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| JP2019528077A5 (hr) | ||
| RU2017134741A (ru) | Полипептиды транспозазы и их применение | |
| ES2732907T3 (es) | Procedimiento de expresión | |
| RU2016114306A (ru) | Антитела со встроенным в лёгкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения | |
| MX2011013544A (es) | Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas. | |
| JP2012531208A5 (hr) | ||
| DK1583830T3 (da) | Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner | |
| HRP20161459T1 (hr) | Protutijela koja se specifično vežu na receptor epidermnog čimbenika rasta | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| US9458244B2 (en) | Single chain multivalent binding protein compositions and methods | |
| EP3167065B1 (en) | Dual cistronic bacterial expression system | |
| JP2016517691A5 (hr) | ||
| MY196874A (en) | Humanized anti-basigin antibodies and the use thereof | |
| RU2017129911A (ru) | Биосенсорная система для быстрого обнаружения определяемых компонентов | |
| RU2015129656A (ru) | Гуманизированное моноклональное антитело, специфичное к синдекану-1 | |
| RU2017102986A (ru) | Новые люциферазы и способы их использования | |
| JP2017525368A5 (hr) | ||
| KR101972899B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질과 C4bp 올리고머화 도메인이 연결된 융합 단백질 및 이의 용도 | |
| CN102719443B (zh) | 一种羧基末端特异的抗人淀粉样蛋白单克隆抗体基因和其编码多肽及应用 | |
| JP2016506239A5 (hr) | ||
| FI3687287T3 (fi) | Humanisoitua c1q-kompleksia ilmentävät jyrsijät | |
| EA202091713A1 (ru) | Биологический синтез аминокислотных цепей для получения пептидов и белков | |
| KR101972894B1 (ko) | 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도 |